New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn's Patients With Fistulizi...(an experience an ongoing cycle of flare-...)

About CIMZIA(R) (certolizumab pegol)

CIMZIA(R) is the only PEGylated anti-TNFa (Tumour Necrosis Factor alpha). CIMZIA(R) has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation.

This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. UCB is developing CIMZIA(R) in rheumatoid arthritis and other autoimmune disease indications. CIMZIA(R) was approved in April 2008 for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy. CIMZIA(R) is a registered trademark of UCB PHARMA S.A. For full prescribing information, please visit http://www.ucb-group.com.

Tuberculosis (frequently disseminated or extrapulmonary at clinical presentation), invasive fungal infections, and other opportunistic infections, have been observed in patients receiving CIMZIA(R). Some of these infections have been fatal. Anti-tuberculosis treatment of patients with latent tuberculosis infection reduces the risk of reactivation in patients receiving treatment with TNF blockers such as CIMZIA(R). However, active tuberculosis has developed in patients receiving CIMZIA(R)whose tuberculin test was negative. Evaluate patients for tuberculosis risk factors and test for latent tuberculosis infection prior t
'/>"/>